Overview

Nasal Spray Study in Sjogren's Dry Eye Disease

Status:
Not yet recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
This study will investigate how well OC-01 (varenicline) nasal spray can treat the signs and symptoms of dry eye disease in those Sjogren's Syndrome. Patients at least 18 years old with moderate-to-severe Sjogren's dry eye disease may be eligible for this study. If you are eligible to participate in the study and you decide to join, there will be 3 study visits over approximately 1 month. You will also self-administer the nasal spray at home every day, 2 times a day during this month.
Phase:
Phase 4
Details
Lead Sponsor:
University of Pennsylvania
Collaborator:
Oyster Point Pharma, Inc.
Treatments:
Varenicline